摘要：
目的:研究可溶性协同刺激分子B7同系物4(soluble B7 homologue 4,sB7-H4)在食管癌前病变患者血清的表达水平,探讨sB7-H4诊断食管癌前病变的临床意义.方法:通过苏木素-伊红(hematoxylin-eosin,HE)染色方法,评价食管病理变化.通过酶联免疫吸附法(enzyme-linked immu-nosorbent assay,ELISA)检测血清sB7-H4和鳞状细胞癌相关抗原2(squamous cell carcinoma antigen-2,SCCA-2)的浓度.结果:食管癌前病变分为低级别上皮内瘤变(low-grade intraepithelial neoplasia,LGIN)和高级别上皮内瘤变(high-grade intraepithelial neoplasia,HGIN).HGIN患者血清SCCA-2浓度显著高于LGIN患者和健康受试者血清SCCA-2浓度(P<0.01,P<0.01).LGIN患者血清sB7-H4浓度显著高于健康受试者血清sB7-H4浓度(P<0.05),并且显著低于HGIN患者血清sB7-H4浓度(P<0.01).sB7-H4在血清的表达与食管组织病理级别呈显著正相关(P<0.0001),而与患者的年龄和性别无关(P=0.7777,P=0.6068).结论:食管癌前病变进程中血清sB7-H4浓度逐渐提高,sB7-H4对于判断食管癌前病变进展程度,是一个有价值的血清标志物.
